Delavirdine Available on Expanded Access

Persons with a CD4 count of 300 or less who are failing other therapy may qualify for an open-label program to use the experimental antiretroviral delavirdine in combination with at least one other antiretroviral.

To be eligible, patients must not be hospitalized, or have "an acute, serious, life-threatening condition," or be treated concurrently with rifampin, rifabutin, astemizole, loratidine, or terfenidine. Patients must not have hemoglobin less than 8.0, neutrophils less than 600, platelets less than 25,000, or creatinine greater than 3.0. There are some additional entry criteria.

Your physician can register you for the program by calling 800/779-0070. Some paperwork will be required, and possibly local IRB approval. This program has already been approved by a national IRB.

For more information, persons in the U.S. and Canada can call 800/432-4702 or 800/779-0070.